Young-age prostate cancer

Journal of Clinical Pathology

Volumn 68, Issue 7, 2015, Pages 511-515

  Hussein, S ^a   Satturwar, S ^b   Van Der Kwast, T ^b  

^a KUWAIT CANCER CONTROL CENTER   (Kuwait)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROSTATE SPECIFIC ANTIGEN; BRCA2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXB13 PROTEIN, HUMAN; TUMOR MARKER;

AGGRESSIVENESS; ARTICLE; AUTOPSY; CANCER MORTALITY; CANCER RISK; CLINICAL FEATURE; ETHNICITY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GLEASON SCORE; HEREDITY; HISTOPATHOLOGY; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; YOUNG AGE PROSTATE CANCER; ADULT; CANCER GRADING; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; MUTATION; ONSET AGE; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; RISK FACTOR;

ADULT; AGE OF ONSET; BRCA2 PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PHENOTYPE; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84933180981     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-202993     Document Type: Article

References (49)

1. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/#age
2. Howlader N, Noone AM, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2011. Bethesda, MD: National Cancer Institute, 2014. http://seer.cancer.gov/csr/1975-2011/
3. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
4. Mitka M. Urology group: Prostate screening should be offered beginning at age 40. JAMA 2009;301:2538-9.
5. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011;117:1210-19. doi:10.1002/cncr.25568
6. Connolly D, Black A, Gavin A, et al. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev 2008;17:271-8.
7. Huben R, Natarajan N, Pontes E, et al. Carcinoma of prostate in men less than fifty years old. Data from American College of Surgeons' National Survey. Urology 1982;20:585-8.
8. Douglas EJ, Lanieri J, Aayala A. Prostatic adenocarcinoma occurring in men under 50 years of age. J Surg Oncol 1972;4:207-16.
9. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer. Cancer 2009;115:2863-71.
10. Wilson JM, Kemp IW, Stein GJ. Cancer of the prostate. Do younger men have a poorer survival rate? Br J Urol 1984;56:391-6.
11. Breslow N, Chan C, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977;20:680-8.
12. Sakr W, Haas G, Cassin B, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-85.
13. Stantinos K, Alevizos A, Sofras F, et al. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: An Autopsy study. Prostate 2006;66:1319-28.
14. Sanchez-Chapado M, Olmedilla G, Cabeza M, et al. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 2003;54:238-47.
15. Soos G, Tsakiris I, Szanto J, et al. The prevalence of prostate carcinoma and it's precursor in Hungary: an autopsy study. Eur Urol 2005;48:739-44.
16. Gronberg H, Damber JE, Jonsson H, et al. Patient age as a prognostic factor in prostate cancer. J Urol 1994;152:892-5.
17. Smith C, Bauer J, Connely R, et al. Prostate cancer in men age 50 years or younger: a review of the department of defense center for prostate disease research multicenter prostate cancer database. J Urol 2000;164:1964-7.
18. Loeb S, Hernandez D, Mangold L, et al. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int 2008;101:1503-6.
19. Schroder F, Hugosson J, Roobol M, et al. Screening and prostate cancer mortality in a randomized European study. N Eng J Med 2009;360:1320-8.
20. Ali K, Gunnar A, Jan-Erik D, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2006;120:170-4.
21. Kim J, Ebertowski J, Janiga M, et al. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int 2013;111:934-40.
22. Ranasinghe W, Kim S, Lawrentschuk N, et al. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia. BJU Int 2014;113:77-83.
23. Powell J, Banerjee M, Sakr W, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer 1999;85:472-7.
24. Powell J, Bock C, Ruterbusch J, et al. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in Black than in White American men and influences racial progression and mortality disparity. J Urol 2010;183:1792-6.
25. Powell J, Vigneau F, Bock C, et al. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev 2014;23:1505-11.
26. Powell J, Heilbrun LK, Sakr W, et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: A multivariate analysis of positive surgical margins. J Urol 1997;9:726-31.
27. Heyns CF. Is prostate cancer more common and more aggressive in African men? Afr J Urol 2006;14:66-74.
28. Pakkanen S, Baffoe-Bonnie AB, Matikainen MP, et al. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet 2007;121:257-67.
29. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003;97:1894-903.
30. Kiciński M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS ONE 2011;6:e27130.
31. Gronberg H, Bratt O, Damber JE, et al. Hereditary prostate cancer: clinical characteristics and survival. J Urol 2002;167:2423-6.
32. Lange E, Johnson A, Wang Y, et al. Genome-wide association scan for variants associated with early-onset prostate cancer. PLoS ONE 2014;9:e93436.
33. Lange E, Salinas C, Zuhlke K, et al. Early onset prostate cancer has a significant genetic component. Prostate 2012;72:147-56.
34. Salinas CA, Tsodikov A, Ishak-Howard M, et al. Prostate cancer in young men: an important clinical entity. Nat Rev Urol 2014;6:317-23.
35. Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269-75.
36. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502-7.
37. Edwards S, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1-12.
38. Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011;105:1230-4.
39. Sigurdsson S, Thorlacius S, Tomasson J, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997;75:758-61.
40. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748-57.
41. Risbridger G, Taylor R, Clouston D, et al. Patient derived xenografts reveal that intraductal carcinoma of prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol 2015;76:496-503.
42. Ewing C, Anna M, Ray MS, et al. Germline mutations in HOXB13 and prostate cancer risk. N Engl J Med 2012;366:141-9.
43. Laitinen V, Wahlfors T, Saaristo L, et al. HOXB13 G84E mutation in Finland: Population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2013;22:452-60.
44. Karlsson R, Aly M, Clements M, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol 2014;65:165-76.
45. Smith S, Palanisamy N, Zuhlke K, et al. HOXB13 G84E-related Familial prostate cancers a clinical, histologic, and molecular survey. Am J Surg Pathol 2014;38:615-26.
46. Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013;23:159-70.
47. Schaefer G, Mosquera JM, Ramoner R, et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis 2013;16:132-8.
48. Huang KC, Dolph M, Donnely B, et al. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. Clin Transl Oncol 2014;16:973-9.
49. Steurer S, Mayer P, Adam M, et al. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur Urol 2014;66:978-81.